Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.29
- Piotroski Score 3.00
- Grade Sell
- Symbol (IART)
- Company Integra LifeSciences Holdings Corporation
- Price $25.53
- Changes Percentage (-4.38%)
- Change -$1.17
- Day Low $25.26
- Day High $26.57
- Year High $45.42
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $33.00
- High Stock Price Target $86.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.51
- Trailing P/E Ratio 60.39
- Forward P/E Ratio 60.39
- P/E Growth 60.39
- Net Income $67.74 M
Income Statement
Quarterly
Annual
Latest News of IART
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Integra Lifesciences Holdings Corp (IART) Q3 2024 Earnings Call Highlights: Navigating ...
Expect mid-single-digit organic growth in 2025 despite quality holds in Q4. No significant hurricane impacts on procedures or IV shortages. $10 million impact from shipping holds in Q4. Gross margin h...
By Yahoo! Finance | 3 days ago -
Liane Moriarty Has Sold 20 Million Books. She Would Rather Not Talk About It.
Liane Moriarty, a successful author, has written best sellers like "Big Little Lies" and "The Husband's Secret." Despite her fame, she remains humble and does not seek personal branding....
By The New York Times | 1 month ago -
In Liane Moriarty's Bustling New Novel, Fate Takes Flight
Liane Moriarty's novel "Here One Moment" unfolds during a flight delay, intertwining passengers' lives with a mysterious woman who predicts their deaths. With complex characters and a slow-burning plo...
By The New York Times | 1 month ago
